Overview

To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.
Phase:
Phase 2
Details
Lead Sponsor:
TaiGen Biotechnology Co., Ltd.
Collaborator:
R&G Pharma Studies Co.,Ltd.